Global pharmaceutical major AstraZeneca on Saturday announced an investment of Rs 1.76 billion in India to expand capabilities and infrastructure at its Global Innovation & Technology Centre (GITC) in Chennai.

This new investment, the third in the past two years in India, will enhance the GITC’s capacity to reinforce its position as a leader in healthcare innovation both globally and within the country, AstraZeneca stated.

“This new investment reflects our ongoing mission to improve patient lives by embedding cutting-edge technologies into every aspect of our work. Chennai continues to evolve as a vital innovation hub, and our continued growth here demonstrates the state’s boundless potential,” said Mr Siva Padmanabhan, Managing Director of AstraZeneca India Pvt Ltd.

The investment will support the expansion of AstraZeneca’s world-class technology and innovation teams, including experts in artificial intelligence, data analytics, machine learning, data science and supply chain analytics, all aimed at transforming healthcare outcomes.

Furthermore, the initiative will accelerate the development of next-generation medicines, support digital and data-driven solutions, and foster future-ready healthcare ecosystems.

Quoting Tamil Nadu Chief Minister MK Stalin, the statement said, “This additional investment in Chennai is a testament to the state’s reputation as a centre of excellence for global innovation.” Mr Stalin added that the partnership would create skilled opportunities, promote knowledge exchange, and strengthen Tamil Nadu’s position as a preferred destination for forward-looking industries.

In addition to its innovative portfolio in specialist disease areas such as oncology, cardiovascular conditions, respiratory illnesses and rare diseases, AstraZeneca noted its strong presence in technology, global business services, and research and development in India. Including the GITC, the company employs more than 5,000 people in the country.